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The majority of endometrioid neoplastic lesions
are believed to follow a continuum of hyperplastic
lesions that range from endometrial hyperplasia
without atypia, to endometrial hyperplasia with
atypia, to well-differentiated endometrial carci-
noma.1,2 Endometrial hyperplasia is defined as a
proliferation of glands of irregular size and shape
with an increase in the glands/stroma ratio.3 It can
appear at any age between puberty and menopause
and appears most frequently in perimenopausal
women. The diagnosis of endometrial hyperpla-
sia is made typically by endometrial biopsy or
curettage after a woman presents to a gynecologist
with abnormal uterine bleeding, including inter-
menstrual or postmenopausal bleeding.
Atypical endometrial hyperplasia has been
associated strongly with progression to endome-
trial carcinoma and the presence of concomi-
tant endometrial carcinoma.4,5 Although atypical
hyperplasia can be treated successfully with pro-
gestins, hysterectomy is recommended for post-
menopausal women with cytologic atypia because
of the high risk of coexistent endometrial carci-
noma and progression to cancer.3
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Background/Purpose: Endometrial hyperplasia is considered a precursor of endometrial carcinoma, but con-
current endometrial carcinoma in patients with endometrial hyperplasia is seen frequently. Our aim was
to examine the risk factors for coexisting endometrial carcinoma in patients with endometrial hyperplasia.
Methods: Between January 1996 and September 2006, 77 patients who underwent hysterectomy for en-
dometrial hyperplasia were enrolled retrospectively. We divided the patients into non-endometrial carci-
noma and endometrial carcinoma groups, depending on the final pathology of hysterectomy and analyzed
the clinical variables of these patients.
Results: The prevalence rate of concurrent endometrial carcinoma in patients with endometrial hyperpla-
sia was 26%. Those with atypical endometrial hyperplasia had a higher rate of coexisting endometrial carci-
noma (54%). In addition to cytologic atypia, body mass index (BMI) was another risk factor. All the patients
with concomitant endometrial carcinoma had at least one risk factor, but almost 50% of the cases in the
non-endometrial group had no risk factors. Half of the women with cytological atypia and BMI > 25 had
coexisting endometrial carcinoma.
Conclusion: When patients are diagnosed with endometrial hyperplasia, surgical intervention should 
be performed in those with cytological atypia and higher BMI because of the possibility of coexisting 
endometrial carcinoma. [J Formos Med Assoc 2009;108(6):502–507]
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Etiological studies have shown that obesity,
diabetes, nulliparity and unopposed estrogen 
exposure of endogenous or exogenous origin are
risk factors for endometrial carcinoma.6 However,
studies on concomitant endometrial carcinoma
and endometrial hyperplasia have focused mostly
on atypical endometrial hyperplasia, and other
related clinical parameters have not been ana-
lyzed extensively.
Here, patients with concurrent endometrial car-
cinoma who underwent hysterectomy for curet-
tage diagnosis of endometrial hyperplasia were
investigated retrospectively. In addition to the
preoperative histology of dilatation and curettage
(D&C) specimens, the clinical variables including
age, menopausal status, obstetrical history, medical
history of diabetes (plasma glucose ≥ 126 mg/dL
after overnight fast) and hypertension (blood pres-
sure >140/90mmHg), and body mass index (BMI)
were investigated. The histological characteristics
and outcome of patients who were diagnosed with
endometrial carcinoma postoperatively were also
recorded.
Patients and Methods
We reviewed retrospectively 77 patients who had
undergone hysterectomy for endometrial hyper-
plasia between January 1996 and September 2006
at the Department of Obstetrics and Gynecology,
National Taiwan University Hospital. A preoper-
ative pathological diagnosis of endometrial hyper-
plasia was obtained by D&C in all patients. The
surgical indications for hysterectomy in these 77
women included cytological atypia, persistent post-
menopausal bleeding, hypermenorrhea, or abnor-
mal bleeding even after medication. Twenty women
were diagnosed with endometrial carcinoma in
their hysterectomy specimens. All of the specimens
were reviewed by a gynecological pathologist.
Depending on the final pathological reports
of hysterectomy, we divided the 77 women into a
non-endometrial carcinoma group (n=57) and an
endometrial carcinoma group (n = 20). As already
mentioned above, we investigated the women by
clinical parameters including age, menopausal sta-
tus, obstetrical history, medical history of diabetes
and hypertension, BMI and preoperative pathol-
ogy with D&C. The distribution of risk factors
among the studied population was also analyzed.
The clinical and pathological characteristics
of the 20 patients diagnosed with endometrial
carcinoma postoperatively were also reviewed.
Initial manifestation, histological grading of the
carcinoma, depth of myometrial invasion, pres-
ence or absence of adjuvant radiotherapy, and re-
currence were included. The histological grading
of endometrial carcinoma was based on FIGO
(International Federation of Gynecology and
Obstetrics) definitions proposed in 1989.7 The
Research and Ethics Committee of National
Taiwan University Hospital approved the study.
Statistical analysis was performed with the 
independent-samples t test and Mann-Whitney
test. Subsequently, multivariate analysis of risk
factors was also employed with a binary logistic
regression model to obtain the adjusted odds
ratio (OR) and 95% confidence interval (CI) for
selective variables. A p value < 0.05 was defined
as significant.
Results
In our survey, the prevalence rate of concurrent
endometrial carcinoma in patients with endome-
trial hyperplasia was 26% (20/77). The median
interval from the diagnosis of endometrial hy-
perplasia to hysterectomy was 4 months. Among
the menopausal women, eight out of 19 were di-
agnosed with endometrial carcinoma postopera-
tively. Four out of five women with diabetes had
concomitant endometrial carcinoma. Fourteen
out of 26 (54%) women with atypical endome-
trial hyperplasia were diagnosed with endome-
trial carcinoma as compared with six out of 51
(12%) women without cytological atypia.
As shown in Table 1, the differences in meno-
pausal status, diabetes, body weight, BMI and 
cytological atypia were statistically significant be-
tween the two groups. After adjusting for potential
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confounders, the risks of cytological atypia (OR,
9.51; 95% CI, 2.18–41.51) and BMI (OR, 1.23;
95% CI, 1.06–1.43) were independent risk factors
for endometrial hyperplasia coexisting with endo-
metrial carcinoma (Table 2). All the patients with
endometrial carcinoma had at least one of the
following four risk factors: menopause, diabetes,
BMI >25, and positive cytological atypia. However,
nearly 50% (28/57) of the non-endometrial car-
cinoma patients had none of these risk factors.
When focusing on the patients with cytological
atypia and BMI > 25, 50% (6/12) had coexisting
endometrial carcinoma. All of these had endo-
metrial carcinoma after hysterectomy, when the
women had cytological atypia and increased BMI,
with menopause or diabetes. The distribution of
the risk factors is summarized in Table 3.
The clinical and pathological characteristics of
the 20 women diagnosed with endometrial carci-
noma postoperatively are reviewed. Eight of these
women had postmenopausal bleeding, two had
intermenstrual bleeding, and 10 complained of
Table 1. Characteristics of patients with non-endometrial carcinoma and endometrial carcinoma classified by
final pathology of hysterectomy*
Non-endometrial carcinoma Endometrial carcinoma 
p
(n = 57) (n = 20)
Age (yr) 48.7 ± 9.1 52.2 ± 10.5 0.207†
Menopause 0.001‡
Yes 11 8
No 46 12
Gravida 3.3 ± 1.7 3.5 ± 1.8 0.691†
Parity 2.5 ± 1.4 2.6 ± 1.4 0.781†
Diabetes mellitus 0.005‡
Yes 1 4
No 56 16
Hypertension 0.716‡
Yes 12 5
No 45 15
Body height (cm) 156.8 ± 6.0 156.9 ± 5.3 0.934†
Body weight (kg) 59.0 ± 10.6 74.5 ± 17.3 0.001†
BMI (kg/m2) 24.0 ± 4.0 30.2 ± 6.9 0.001†
D&C result < 0.001‡
AEH 12 14
Non-AEH 45 6
*Data presented as mean ± standard deviation or n; †independent samples t test; ‡Mann-Whitney test. BMI = body mass index; D&C =
dilatation and curettage; AEH = atypical endometrial hyperplasia.
Table 2. Multivariate analysis of risk factors for coexistence of endometrial hyperplasia and endometrial
carcinoma
Odds ratio* 95% confidence interval p
Menopause 2.96 0.39–22.38 0.294
Diabetes mellitus 14.72 0.78–278.39 0.073
Body mass index 1.23 1.06–1.43 0.006
Cytological atypia 9.51 2.18–41.51 0.003
*Adjusted for menopause, diabetes mellitus, body mass index and cytological atypia by binary logistic regression.
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several episodes of hypermenorrhea that had not
occurred since menarche. The final pathological re-
sults were all endometrioid type adenocarcinoma.
Eighteen patients had endometrial carcinoma
with histological grade 1 and two had histological
grade 2. Eight patients (40%) had lesions confined
to the endometrium, nine (45%) had < 50% myo-
metrial invasion and three (15%) had > 50% 
myometrial invasion. Two of the four women who
received postoperative adjuvant radiotherapy had
tumor emboli in the lymphovascular space. Only
one of the 20 women had cervical and adnexal
involvement. Her preoperative pathology with
D&C was atypical endometrial hyperplasia. After
completing adjuvant radiotherapy, she had vaginal
recurrence 12 months later. One of the 20 patients
was lost to follow-up but the others had regular
follow-up at our hospital after their operation.
Discussion
Endometrial hyperplasia usually evolves when
there is a background of proliferative endometrium
as a result of protracted estrogenic stimulation, in
the absence of progestin influence. A classification
system for endometrial hyperplasia has been de-
veloped based on morphological and cytological
features.3 However, simple hyperplasia without
atypia is closest to the normal proliferative endo-
metrium, and the most severe form of complex
atypical hyperplasia resembles well-differentiated
endometrioid adenocarcinoma in biological and
morphological aspects.8 Based on several stud-
ies, a preoperative diagnosis of complex atypical 
hyperplasia is followed frequently by carcinoma
after hysterectomy. The concomitant rate of endo-
metrial carcinoma in patients with atypical endo-
metrial hyperplasia varies from 15% to 52%.9–16
In our study, 14 of 26 women (54%) with atypi-
cal endometrial hyperplasia were diagnosed with
endometrial carcinoma after hysterectomy, and
only six of 51 patients (12%) with endometrial
hyperplasia without cytological atypia had con-
current endometrial carcinoma after hysterec-
tomy. These results are compatible with previous
studies.
The high incidence of coexisting endometrial
carcinoma in patients with endometrial hyper-
plasia may lead to inadequate surgical staging. 
A review of the histology before surgery has been
undertaken; however, the result was disappoint-
ing because of the low reproducibility among
pathologists.17 Furthermore, complex atypical hy-
perplasia and well-differentiated endometrioid
adenocarcinoma share so many important char-
acteristics, including microsatellite instability and
mutation of PTEN, CTNNB1 and k-ras; therefore,
Table 3. Distribution of risk factors among patients with non-endometrial carcinoma and endometrial
carcinoma
Risk factors
Non-endometrial Endometrial
carcinoma (n = 57) carcinoma (n = 20)
None 28 0
One 21 6
Cytological atypia 6 2
BMI > 25* 13 3
Diabetes 0 1
Menopause 2 0
Cytological atypia and BMI > 25 6 6
Cytological atypia and BMI > 25 0 4
with menopause or diabetes
All four risk factors 0 1
*BMI > 25 kg/m2 is defined as overweight by the World Health Organization. BMI = body mass index.
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tests for any one or a combination of these mo-
lecular markers cannot definitely separate these
two entities.7,18,19 Therefore, more efforts should
be explored to identify the coexisting endome-
trial carcinoma in patients with endometrial 
hyperplasia.
According to etiological studies of endome-
trial cancer, age, underlying ovarian disease, dia-
betes, obesity and exogenous hormone exposure
are thought to be risk factors for endometrial car-
cinoma.6 Our results showed that the clinical vari-
ables of menopausal status, diabetes, body weight
and BMI were associated significantly with con-
current endometrial carcinoma. In addition to
cytological atypia, BMI was also shown to be an
independent risk factor by multivariate analysis.
Increased body weight has been confirmed as a
risk factor for endometrial hyperplasia and ade-
nocarcinoma in several studies.6,20,21 There are
several possible mechanisms proposed for ele-
vated body mass in endometrial carcinogenesis.
First, a weight-related increase in insulin and 
insulin-like growth factor-I has been noted for
endometrial growth.22,23 Second, cytokines24–26
produced from fat tissue and transcription fac-
tors27,28 related to cellular lipid metabolism and
tumorigenesis have also been found.
Here, the mean body weight and BMI of all
the women studied were 63.0 kg and 25.6 kg/m2
preoperatively, which were not particularly high.
However, when comparing the mean body weight
and BMI between women with endometrial car-
cinoma and non-endometrial carcinoma, they
were 74.5 kg versus 59 kg and 30.2 kg/m2 versus
24 kg/m2, respectively, and the differences were
statistically significant. Therefore, more clinical
evidence might be needed to establish whether
higher body weight and BMI lead more readily
to concomitant endometrial carcinoma. More
studies are needed to confirm our finding that
patients with increased BMI and cytological atypia
had a high possibility of coexisting endometrial
malignancy.
The final pathology of all the women with 
coexistent endometrial carcinoma in our series
showed histological grade 1 or 2 endometrioid
adenocarcinoma. This was in keeping with pre-
vious studies.3,10 Myometrial invasion in these 
patients is seen frequently, however, infiltration
is usually observed in the inner half of the myo-
metrium.12 Trimble et al stated that all of these
cases also have good prognosis without recur-
rence.12 Although three of our 20 patients (15%)
had > 50% myometrial invasion, only one (5%)
patient had recurrence.
In conclusion, the concurrent rate of endome-
trial carcinoma in patients diagnosed with endo-
metrial hyperplasia preoperatively was 26%. The
prognosis was relatively good with a low recurrence
rate. In addition to cytological atypia, increased
BMI was another risk factor for coexisting endo-
metrial hyperplasia and endometrial carcinoma.
Therefore, when women have D&C diagnosis of
endometrial hyperplasia, particularly with cytolo-
gical atypia and increased BMI, surgical interven-
tion should be considered for the high possibility
of concomitant endometrial carcinoma, rather
than treatment with progestin control.
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